A Bloomberg piece on "super responders" featured Lynn M. Schuchter, MD, chief of Hematology/Oncology and one of her patients who was diagnosed with advanced melanoma five years ago. The then 65-year-old grandmother was a enrolled in a clinical trial with a drug called CD40, and remains disease free to this day. That and similar responses are of great interest to researchers, looking to pinpoint cancer patients’ genetic advantage. Such information could help better identify responders, targeted therapies and even new treatment approaches. "While we've made huge advance in immunotherapy in recent years, we are still in the dark ages as to who should get the drug and why they are benefiting," Schuchter said.